Benefits
Body Weight, Waist, and BMI Reduction
The Genta 2009 RCT (n=55, 120 days, double-blind, placebo-controlled) in obese pre-menopausal women showed significant decreases in body weight, waist circumference, and BMI with yacon syrup at 0.14 g FOS/kg/day. Effect size was modest but clinically meaningful in this population.
Insulin Resistance Improvement
Genta 2009 documented significant decreases in fasting serum insulin and HOMA-IR (Homeostasis Model Assessment for Insulin Resistance) over 120 days. All participants had baseline elevated HOMA-IR (>2.70 cutoff). No effect on fasting glucose (already normo-glycemic). Effects align with FOS-mediated GLP-1 elevation and gut microbiome modulation.
LDL Cholesterol Reduction
Genta 2009 found a significant decrease in serum LDL-cholesterol with yacon syrup, while total cholesterol and triglycerides were not significantly changed. The 2025 Pereira systematic review (7 trials, n=161) confirmed LDL reduction as a consistent finding across yacon trials.
Increased Defecation Frequency and Satiety
Genta 2009 documented increased defecation frequency and satiety sensation with yacon syrup. FOS is a well-established prebiotic and bulk-forming dietary fiber; satiety effects likely involve FOS-mediated GLP-1 and PYY elevation. Gut transit benefits are consistent across studies.
Prebiotic / Gut Microbiome Support
FOS is selectively fermented by Bifidobacterium and Lactobacillus species, supporting beneficial gut microbiome composition. This is the same mechanism as inulin and other fructan prebiotics. The 2025 Pereira systematic review noted improvements in intestinal transit and gut microbiota across yacon trials.
Mechanism of action
Fructooligosaccharide (FOS) Prebiotic Effect
Yacon syrup is exceptionally rich in inulin-type FOS (40-70% of dry weight) — among the highest natural sources known. FOS is non-digestible by human enzymes but selectively fermented by colonic Bifidobacterium and Lactobacillus, producing short-chain fatty acids (SCFAs: acetate, propionate, butyrate) with metabolic and anti-inflammatory benefits.
GLP-1 and PYY Elevation (Incretin/Satiety Hormones)
Colonic SCFA production from FOS fermentation stimulates L-cell secretion of GLP-1 (incretin, postprandial insulin enhancer) and PYY (peptide YY, satiety hormone). This explains the satiety and insulin sensitivity benefits documented in the Genta 2009 trial.
Reduced Caloric Density (Low-Glycemic Sweetener)
FOS provides ~1.5-2 kcal/g vs. ~4 kcal/g for sucrose — and most of those calories come from colonic SCFAs that are partially used by gut bacteria. As a sweetener replacement, yacon syrup substantially reduces glycemic load and net caloric impact.
Bulk Stool Formation and Transit
Like other soluble fibers, FOS adds water-binding bulk to stool and may accelerate colonic transit. This explains the increased defecation frequency in Genta 2009 and supports general gut health applications.
Modest Mineral Absorption Enhancement
FOS may modestly enhance calcium and magnesium absorption via colonic SCFA-induced mineral solubilization. Effects are real but usually small; relevance for osteoporosis prevention is mechanism-based rather than RCT-confirmed for yacon specifically.
Clinical trials
Double-blind, placebo-controlled trial. Two doses of yacon syrup (0.29 g and 0.14 g FOS/kg/day) vs. placebo for 120 days in obese pre-menopausal women. Anthropometric measurements, blood glucose, calcium, lipid and insulin concentrations, HOMA-IR. (Genta, Cabrera, Habib, Pons, Carillo, Grau, Sánchez 2009, Clin Nutr)
Obese, slightly dyslipidemic pre-menopausal women with baseline insulin resistance (HOMA-IR > 2.70).
Recommended dose without GI side effects: 0.14 g FOS/kg/day. Significant decreases in body weight, waist circumference, and BMI. Significant decreases in fasting serum insulin and HOMA-IR. Significant LDL cholesterol reduction. Increased defecation frequency and satiety sensation. Fasting glucose unchanged. Higher dose (0.29 g/kg) caused GI side effects. Foundational RCT establishing yacon syrup as a beneficial functional food for obese insulin-resistant women.
PRISMA-compliant systematic review of yacon syrup clinical trials over the last decade. Searched Medline (PubMed), Science Direct, Embase, Scopus, SciELO through October 2024. Inclusion: clinical trials of yacon syrup on glycemic control, lipid profile, insulin sensitivity, appetite regulation, gut microbiota in healthy/overweight/obese individuals. (Pereira et al. 2025, Nutrients)
7 RCTs included, totaling 161 participants from diverse populations.
Yacon syrup supplementation demonstrated significant reductions in fasting insulin, HOMA-IR, and LDL cholesterol, alongside improvements in satiety and intestinal transit. Findings were consistent across trial heterogeneity. Authors noted evidence quality concerns (small sample sizes, dose variability) and called for larger trials.
Randomized, double-blind, placebo-controlled clinical trial of yacon flour vs. placebo in overweight adults. Outcomes: body composition, intestinal function. (Machado, da Silva, Chaves, Alfenas 2019, Clin Nutr ESPEN)
Overweight adults.
Yacon flour consumption improved body composition and intestinal function vs. placebo. Provides additional evidence beyond syrup form that yacon-derived FOS supports weight management and gut function. Effect sizes modest but consistent with mechanism.
About this ingredient
Yacon (Smallanthus sonchifolius) is a perennial Asteraceae plant native to the Andean regions of South America. It produces sweet-tasting tubers that are exceptionally rich in fructooligosaccharides (FOS) — typically 40-70% of dry weight. Commercial yacon syrup is made by extracting and concentrating the tuber juice while preserving the FOS content (typically 40-65% FOS in finished syrup).
Yacon syrup has a sweet, molasses-like flavor and can substitute for sugar in low-glycemic applications. EVIDENCE: The Genta 2009 RCT is the foundational human evidence — significant decreases in body weight, waist circumference, BMI, fasting insulin, HOMA-IR, and LDL cholesterol with 0.14 g FOS/kg/day for 120 days in obese pre-menopausal women. The 2025 Pereira systematic review (7 trials, 161 participants) confirms these findings as consistent across studies.
Mechanism is well-established prebiotic FOS effects: SCFA production, GLP-1/PYY elevation, microbiome modulation. SAFETY: Excellent — yacon is consumed as a traditional food. Main practical concern is dose-dependent GI side effects above ~10 g FOS/day.
Genuinely useful as a functional sweetener for those targeting metabolic health, though not a substitute for evidence-based diabetes or obesity treatment.